

Multiple Sclerosis Research

Multiple Sclerosis A study to evaluate the safety and efficacy of oral Dalfampridine Extended Release tablets in MS patients

- 18-70 years old
- Diagnosed with MS

Multiple Sclerosis A study to evaluate patient outcomes, safety and tolerability of Fingolimod FTY720 with RRMS patients who are candidates for MS therapy change.

- 18 – 65 years old
- Must be receiving continuous treatment with an approved DMT for MS for 6 months prior
- Naïve to treatment with Fingolimod FTY720

Multiple Sclerosis A study of the efficacy and safety of Teriflunomide in RRMS patients who are treated with interferon-beta

- 18 – 55 years old
- Must be currently treated with interferon-beta (INF- β)
- 1 relapse within the past 12 months

Multiple Sclerosis A study to evaluate the efficacy and safety of two year treatment with teriflunomide in patients with a first clinical episode suggestive of MS

- 18-55 years old
- 1st onset of MS symptoms, occurring within 30 days, such as optic neuritis, spinal cord syndrome, brainstem/ cerebellar syndromes

Multiple Sclerosis JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or considering Treatment with Tysabri®

Epilepsy/Seizure Research

Epilepsy An efficacy and safety study of Eslicarbazepine Acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures

- 16 years or older
- Diagnosis of epilepsy for 12 months
- Currently treated with 1 or 2 AED's and in a stable dose regimen 1 month prior
- At least 4 partial-onset seizures on the 4 weeks prior to screening (includes subtype of simple partial, complex partial and partial seizures evolving to secondarily generalized)

Parkinson's Disease Research

Parkinson's Disease A study to evaluate the efficacy and safety of pramipexole in subjects with moderate to severe Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Must be on a stable dose of L-dopa for approximately 2 or more years

Parkinson's Disease A study to evaluate the efficacy and safety of pramipexole in subject with early Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Can't be on L-dopa or dopamine agonist

Parkinson's Disease A study to determine the efficacy and safety of a dose range of 50 to 100mg/daily of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations treated with a stable dose of levodopa (Sinemet)

- 30-80 years old
- Diagnosis of idiopathic PD of more than 5 years
- On stable dose of levodopa 4 weeks prior

Parkinson's Disease A study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic PD, treated with dopamine agonist

- 30-80 years old
- Diagnosis of idiopathic PD less than 5 years
- On stable dose of dopamine agonist 4 weeks prior

Neuropathic Pain Research

Neuropathic Pain A study to Evaluate the Efficacy, Safety and Tolerability of study medications in Patients with Postherpetic Neuralgia and Post-Traumatic Neuralgia, Followed by a Safety Extension and an Open-Label Safety Extension.

- 18 – 80 years old
- Have chronic neuropathic pain and are currently taking neuropathic pain medication that are not adequately controlled
- Diagnosis of Postherpetic Neuralgia (PHN)
- Diagnosis of Post-Traumatic Neuralgia